![]() ![]() This uptake can also be seen in a variety of other tumor types or other pathologic conditions, or might occur as a normal variant. The uptake of gallium Ga 68 dotatate reflects the level of somatostatin receptor density in NETs. NETs have receptors for somatostatin, a hormone that regulates the endocrine system. ![]() NETs are rare benign or malignant tumors that develop in the hormone-producing cells of the body's neuroendocrine system, which are found in the stomach, intestines, pancreas, lungs, and other locations. Netspot is marketed by Advanced Accelerator Applications USA, Inc.Gallium Ga 68 dotatate is a radioactive diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults and pediatric patients. Orphan drug designation provides incentives such as tax credits, user fee waivers, and eligibility for orphan drug exclusivity to assist and encourage the development of drugs for rare diseases. Priority review status is granted to applications for drugs that, if approved, would be a significant improvement in safety or effectiveness in the treatment of a serious condition. The FDA granted Priority Review and orphan drug designations for Netspot. Netspot contributes to overall long-term cumulative radiation exposure, and patients should drink and urinate as often as possible during the first hours following administration to help reduce this risk. No serious adverse reactions have been identified. ![]() The results of all three studies confirmed the usefulness of Ga 68 dotatate images in finding the location of the neuroendocrine tumours. The first compared Ga 68 dotatate images of NETs to images obtained with an approved drug, and then confirmed with computed tomography (CT) and/or magnetic resonance imaging (MRI) the second evaluated Ga 68 dotatate images using histopathology, or clinical follow up as reference standards and the third evaluated patients with NET recurrence using Ga 68 dotatate images. Three studies established the safety and effectiveness of Netspot. The uptake of Ga 68 dotatate may need to be confirmed by histopathology or other assessments. This uptake can also be seen in a variety of other tumour types or other pathologic conditions, or might occur as a normal variant. The uptake of Ga 68 dotatate reflects the level of somatostatin receptor density in NETs. Netspot is supplied as a sterile, single-dose kit for preparation of Ga 68 dotatate injection for intravenous use. This information is important for planning the appropriate course of therapy.” “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. "Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical," said Libero Marzella, MD, PhD, director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research. Ga 68 dotatate, a positron emitting analogue of somatostatin, works by binding to such receptors. These cells are found throughout the body in organs, such as the stomach, intestines, pancreas, lungs and other locations. NETs are rare benign or malignant tumours that develop in the hormone-producing cells of the body’s neuroendocrine system. This radioactive probe will help locate tumours in adult and pediatric patients with rare somatostatin receptor positive neuroendocrine tumours (NETs). On 1 June, 2016 the US Food and Drug Administration (FDA) approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |